24 May 2018 - - The European Commission has granted London, England-based HIV treatment-focused company ViiV Healthcare marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) once-daily, single-pill regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, the company said.
The approval is for treatment of adults who are virologically suppressed (HIV-1 RNA